A Study to Evaluate IBI112 in the Treatment of Psoriasis With Moderate to Severe Plaque Psoriasis
Launched by INNOVENT BIOLOGICS (SUZHOU) CO. LTD. · Dec 1, 2022
Trial Information
Current as of January 13, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Diagnosis of plaque-type psoriasis with or without psoriatic arthritis for at least 6 months prior to first administration of any study agent
- • 2. Must be a candidate for phototherapy or systemic treatment for psoriasis (either new to treatment or having had previous treatment)
- Exclusion Criteria:
- • 1. History of or current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, cerebral, or psychiatric disease
- • 2. Participant has history of erythrodermic psoriasis, generalized or localized pustular psoriasis, medication-induced or medication-exacerbated psoriasis, or new onset guttate psoriasis
- • 3. Has received any therapeutic agent directly targeted to IL-17within 6 months of the first administration of study agent
- • 4. Has received any therapeutic agent directly targeted toTNF-a within 3 months of the first administration of study agent
- • 5. Has received any conventional therapeutic agent within 1 months of the first administration of study agent
- • 6. Has received any topic therapeutic agent within 2 weeks of the first administration of study agent
About Innovent Biologics (Suzhou) Co. Ltd.
Innovent Biologics (Suzhou) Co., Ltd. is a leading biotechnology company dedicated to the development and commercialization of innovative biologic therapies for the treatment of cancer, autoimmune diseases, and other serious conditions. Founded in 2011, Innovent focuses on the discovery and development of monoclonal antibodies and other biologic agents, leveraging advanced technology platforms to address unmet medical needs. With a strong commitment to research and development, the company collaborates with international partners and healthcare professionals to bring cutting-edge therapeutics to market, ultimately improving patient outcomes and quality of life.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, Shanghai, China
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials